Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Population Pharmacokinetics of Anti-infectious Drugs in Children (PHARMA-A)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by University Hospital, Bordeaux
Information provided by (Responsible Party):
University Hospital, Bordeaux Identifier:
First received: April 27, 2011
Last updated: August 14, 2014
Last verified: August 2014

The Pharm A project is a French national collaborative project aiming to determine the population pharmacokinetics of ceftazidime, ciprofloxacin, and voriconazole in paediatric patients aged one month to five years.

Condition Intervention
Drug: Ceftazidime
Drug: Ciprofloxacin
Drug: Voriconazole

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Population Pharmacokinetics Of Ceftazidime, Ciprofloxacin And Voriconazole In Paediatric Young Patients (< 12 Years Old)

Resource links provided by NLM:

Further study details as provided by University Hospital, Bordeaux:

Primary Outcome Measures:
  • Population pharmacokinetic parameters and factors explaining variability [ Time Frame: Between 2 and 4 days after the begining of the treatment ] [ Designated as safety issue: No ]

    Population Pharmacokinetic Parameters and variability factors (Sex, Age, Genetic factors...) for ceftazidime, ciprofloxacin and voriconazole.

    According to the age of participants, 2 or 3 bloods sampling will be take between 2 and 4 days after the beginning of the treatment.

Secondary Outcome Measures:
  • Covariability factors explaining the variability (age, biological data, pharmacokinetics factors, associated treatments...) [ Time Frame: Between 2 and 4 days after the beginning of the treatment ] [ Designated as safety issue: No ]

Estimated Enrollment: 350
Study Start Date: June 2011
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Patients treated with Ceftazidime Drug: Ceftazidime
Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
Experimental: Patients treated with Ciprofloxacin Drug: Ciprofloxacin
Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
Experimental: Patients treated with Voriconazole Drug: Voriconazole
Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.

Detailed Description:

The licensing process was introduced in order to ensure that medicines are safe, effective and of high quality. However, over 50% of children admitted to hospital in France and Europe will receive an unlicensed or off-label medicine. This occurs for most drugs in children less than 6 years of age. They represent a particularly vulnerable subgroup of the paediatric population.

There are major practical and ethical issues in relation to studying medicines in paediatric patients aged 5 years or less.

  • They represent only a small part of the population as compared to older children and adults, and the variation of specific types of diseases in this young subpopulation is higher than in the paediatric counterpart. There are major differences in drug disposition in the different age groups.
  • There is a need for suitable methodological approaches for clinical trials
  • There are major ethical issues It is essential, therefore, to recruit children from various regions in France in order to obtain a critical sample size of sufficient magnitude and to conduct scientific sound studies. This will be achieved by performing Pharm A, a population pharmacokinetic study of three different anti infectious agents (ceftazidime, ciprofloxacin, voriconazole) and identify covariates including pharmacogenetic biomarkers that explain pharmacokinetic variability.

After parental informed consent, sampling strategy will be randomized depending on the drug and the age group (2 samples in patients below 2 years and 3 samples in patients from 2 to 5 years).


Ages Eligible for Study:   up to 6 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children aged 28 days to 11 years (< 12 years)
  • Receiving one of the following drugs for therapeutic reasons : ceftazidime, ciprofloxacin, voriconazole
  • Representative for the clinician, a condition requiring the use of these molecules
  • Informed consent signed by the two parents or legal representative
  • Child affiliated to the national social security system

Exclusion Criteria:

Not Applicable

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01344512

Contact: Stéphanie Bui, Dr (33) 5 56 79 87 37
Contact: Michael Fayon, Pr (33) 5 56 79 98 24

CHU de Bordeaux, Hôpital Pellegrin Recruiting
Bordeaux, France, 33076
Contact: Stéphanie BUI, Dr    (33) 5 56 79 87 37   
Principal Investigator: Stéphanie BUI, Dr         
Sub-Investigator: Michael FAYON, Pr         
Sub-Investigator: Cécile VERITE, Dr         
Sub-Investigator: Paul NOLENT, Dr         
Hospices Civils de Lyon Recruiting
Bron, France, 69500
Contact: Yves BERTRAND, Pr   
Principal Investigator: Yves BERTRAND, Pr         
CHU Clermont Ferrand Recruiting
Clermont Ferrand, France, 63000
Contact: François Demeocq, Pr   
Principal Investigator: François Demeocq, Pr         
CHU de Dijon Recruiting
Dijon, France, 21079
Contact: Marc BARDOU   
Principal Investigator: Marc BARDOU, Pr         
Sub-Investigator: Frédéric HUET, Pr         
CHU de Grenoble Recruiting
Grenoble, France, 38043
Contact: Isabelle PIN, Dr         
Principal Investigator: Isabelle PIN, Dr         
CHRU Lille Recruiting
Lille, France, 59037
Contact: Frédéric Gottrand, Pr         
Principal Investigator: Frédéric GOTTRAND, Pr         
AP-HM, Hôpital La Timone Recruiting
Marseille, France, 13005
Contact: Michel Tsimaratos, Pr         
Principal Investigator: Michel Tsimaratos, Pr         
CHU Montpellier Recruiting
Montpellier, France, 34925
Contact: Gilles Cambonie, Pr   
Principal Investigator: Gilles CAMBONIE, Pr         
AP-HP - Hôpital Robert Debré Recruiting
Paris, France, 75019
Contact: Evelyne Jacz-Aigrain, Pr   
Principal Investigator: Evelyne Jacz-Aigrain, Pr         
APHP - Hôpital NEcker Recruiting
Paris, France, 75015
Contact: Jean-Marc Treluyer, Pr         
Principal Investigator: Jean-Marc Treluyer, Pr         
CHU Poitiers Recruiting
Poitiers, France, 86000
Contact: Régis Hankard, Dr   
Principal Investigator: Régis HANKARD, Dr         
CHU Rouen Recruiting
Rouen, France, 76031
Contact: Eric MALLET   
Principal Investigator: Eric MALLET, Pr         
CHU Toulouse Recruiting
Toulouse, France, 31059
Contact: Jean-Pierre SALLES, Pr   
Principal Investigator: Jean-Pierre SALLES, Pr         
CHU tours Recruiting
Tours, France, 37044
Contact: François Labarthe   
Principal Investigator: François LABARTHE, Pr         
Sponsors and Collaborators
University Hospital, Bordeaux
Principal Investigator: Stéphanie Bui, Dr University Hospital Bordeaux, France
  More Information

No publications provided

Responsible Party: University Hospital, Bordeaux Identifier: NCT01344512     History of Changes
Other Study ID Numbers: CHUBX 2010/36
Study First Received: April 27, 2011
Last Updated: August 14, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by University Hospital, Bordeaux:

Additional relevant MeSH terms:
14-alpha Demethylase Inhibitors
Anti-Bacterial Agents
Anti-Infective Agents
Antifungal Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on March 03, 2015